Venetoclax and Obinutuzumab for Front-line Treatment of Chronic Lymphocytic Leukemia

Deborah M. Stephens


Venetoclax in combination with obinutuzumab is an efficacious and tolerable combination that provides a fixed-duration, chemotherapy-free option for patients with previously untreated chronic lymphocytic leukemia (CLL). With the expanding number of therapeutic alternatives available for CLL, discussion of efficacy and potential adverse effects are paramount to formulating the optimal treatment regimen for each individual patient. Many ongoing studies will further define the ideal combination and long-term efficacy of these novel therapies in a prospective manner.

  • Submitted June 28, 2019.
  • Revision received August 30, 2019.
  • Accepted August 31, 2019.